Abstract：
Prostate cancer (PC) and Ovarian cancer (OC) are two of the most common types of cancer that affect the reproductive systems of older men and women. These cancers are associated with a poor quality of life among the aged population. Therefore, finding new and innovative ways to detect, treat, and prevent these cancers in older patients is essential. Finding biomarkers for these malignancies will increase the chance of early detection and effective treatment, subsequently improving the survival rate. Studies have shown that the prevalence and health of some illnesses are linked to an impaired immune system. However, the age-associated changes in the immune system during malignancies such as PC and OC are poorly understood. Recent research has suggested that the excessive production of inflammatory immune mediators, such as interleukin-6 (IL-6), interleukin-8 (IL-8), transforming growth factor (TGF), tumor necrosis factor (TNF), CXC motif chemokine ligand 1 (CXCL1), CXC motif chemokine ligand 12 (CXCL12), and CXC motif chemokine ligand 13 (CXCL13), etc., significantly impact the development of PC and OC in elderly patients. Our review focuses on the latest functional studies of pro-inflammatory cytokines (interleukins) and CXC chemokines, which serve as biomarkers in elderly patients with PC and OC. Thus, we aim to shed light on how these biomarkers affect the development of PC and OC in elderly patients. We also examine the current status and future perspective of cytokines (interleukins) and CXC chemokines-based therapeutic targets in OC and PC treatment for elderly patients.
摘要：
前列腺癌（PC）和卵巢癌（OC）是影响老年男性和女性生殖系统的两种最常见的癌症类型。这些癌症与老年人群的生活质量差有关。因此,寻找新的和创新的方法来检测，请客,在老年患者中预防这些癌症至关重要。寻找这些恶性肿瘤的生物标志物将增加早期发现和有效治疗的机会，提高生存率。研究表明，某些疾病的流行和健康与免疫系统受损有关。然而,对PC和OC等恶性肿瘤期间免疫系统的年龄相关变化了解甚少。最近的研究表明，炎性免疫介质的过度产生，如白细胞介素-6（IL-6），白细胞介素-8（IL-8），转化生长因子（TGF），肿瘤坏死因子(TNF),CXC基序趋化因子配体1（CXCL1），CXC基序趋化因子配体12（CXCL12），和CXC基序趋化因子配体13（CXCL13），等。,显著影响老年患者PC和OC的发展。我们的综述集中在促炎细胞因子（白介素）和CXC趋化因子的最新功能研究，作为老年PC和OC患者的生物标志物。因此，我们旨在阐明这些生物标志物如何影响老年患者PC和OC的发展.我们还研究了基于细胞因子（白介素）和CXC趋化因子的治疗靶标在老年患者OC和PC治疗中的现状和未来前景。
